Puccio David J, Wei Chris Z, Pillai Abhinav, Deng Hansen, Hadjipanayis Constantinos G, Niranjan Ajay, Lunsford L Dade
School of Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
J Neurooncol. 2025 Oct 22;176(1):35. doi: 10.1007/s11060-025-05306-4.
The role of stereotactic radiosurgery (SRS) for patients with brain metastases from nasopharyngeal carcinoma (NPC) has yet to be established. The authors present a single-institution experience of NPC brain metastases patients who underwent SRS.
Our SRS database of 18,000 patients from 1989 to 2024 identified 44 metastatic NPC patients (31 male) with 68 total brain metastases (median age: 58.5 years, range: 33-80). Twenty-four patients underwent whole brain fractionated radiation therapy (WBRT) and 20 patients underwent surgical resection before SRS. The median margin dose was 16 Gy (range: 10-25). The median cumulative tumor volume was 7.6 cubic centimeters (cc) (range: 0.032-186.66).
The median overall survival (OS) from SRS was 9 months (range: 0-86) with local tumor progression in 11 patients after SRS at a median time of 4 months (range: 2-36). Local tumor control was achieved in 56 of the 68 metastases (82.4%). Five patients developed new brain metastases at a median of 6 months (range: 3-84) following SRS. One patient experienced adverse radiation effects (AREs).
Metastatic spread to the brain from NPC occurs late in the course of primary disease. In our experience non-invasive SRS optimized outcomes and preserved quality of life. Although historically used as a salvage option after surgery and radiation therapy, its role as a primary strategy deserves further utilization in patients with brain metastases from primary NPC tumors.
立体定向放射外科治疗(SRS)在鼻咽癌(NPC)脑转移患者中的作用尚未确定。作者介绍了一家机构对接受SRS治疗的NPC脑转移患者的经验。
我们1989年至2024年的18000例患者的SRS数据库中,确定了44例转移性NPC患者(31例男性),共68处脑转移灶(中位年龄:58.5岁,范围:33 - 80岁)。24例患者在SRS前接受了全脑分割放疗(WBRT),20例患者在SRS前接受了手术切除。中位边缘剂量为16 Gy(范围:10 - 25)。中位累积肿瘤体积为7.6立方厘米(cc)(范围:0.032 - 186.66)。
SRS后的中位总生存期(OS)为9个月(范围:0 - 86),11例患者在SRS后出现局部肿瘤进展,中位时间为4个月(范围:2 - 36)。68处转移灶中有56处(82.4%)实现了局部肿瘤控制。5例患者在SRS后中位6个月(范围:3 - 84)出现新的脑转移。1例患者出现了放疗不良反应(AREs)。
NPC脑转移在原发性疾病病程后期发生。根据我们的经验,非侵入性SRS优化了治疗效果并保留了生活质量。尽管SRS在历史上被用作手术和放疗后的挽救性选择,但其作为主要策略在原发性NPC肿瘤脑转移患者中的作用值得进一步应用。